Early Tracking of Childhood Health Determinants (ETCHED) Study
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · NCT03481829
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 0 mo–99 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Observational
- Target enrollment
- 1500
- US sites recruiting
- 1
- Study start
- April 14, 2022
- Record last updated
- October 16, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
Background
Children s weight has increased sharply in recent years. This may put them at higher risk for health problems. High blood glucose in a pregnant mother and too much weight gain during pregnancy also may have long-term effects on the child s health. Children who become overweight or obese during childhood tend to remain so as adults. Researchers want to study many risk factors during and after pregnancy, and how these affect a child s development. They will also follow the mother s health and well-being after pregnancy.
Objectives
To learn how a pregnant mother s environment, lifestyle, and health conditions may affect her child s growth and development from birth until adulthood.
Eligibility
American Indian/Alaska Native (AI/AN) or Hispanic adult pregnant women and their offspring.
Design
Mothers will have 3 visits during pregnancy.
In the child s first year, mothers will have 2 visits and their child will have 4.
Children will have 2 visits in their second year and 1 each year until they turn 18.
Mothers will have a visit 2 years after birth and 4-5 years later.
Both the mother and child s medical records will be reviewed. They will have physical exams and give blood and stool samples.
Mothers may give cord blood and placenta samples. They will give breastmilk and urine samples. They will fill out questionnaires.
They will have an ultrasound. They may get an activity monitor.
Mother and child will be followed until the child s 18th birthday.
...
Conditions: Diabetes Mellitus; Obesity; Fatty Liver
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
- INCLUSION CRITERIA:
In order to be eligible to participate in this study, an individual must meet all of the following criteria:
- Pregnant women aged 18 years or older (pregnancy confirmed by urine or serum pregnancy test, or ultrasound examination)
- American Indian or Hispanic by self-report
- Agree to continue with research study participation (both mother and their offspring), for at least 3 years after delivery.
In case where a pregnant mother is carrying multiple fetuses (multiple pregnancy), she will be eligible to participate in this study and all her live newborns, as a result of that pregnancy, will be eligible for participation in this study. Mothers will also be eligible to participate with any consecutive pregnancies.
EXCLUSION CRITERIA
An individual who meets any of the following criteria will be excluded from participation in this study:
- Women who are incarcerated or are unable to consent.
- Women whose fetus is not viable or are not planning to continue the pregnancy.
Recruiting US locations
NIDDK, Phoenix
Phoenix, AZ 85014
Study contacts (from the official record)
- Madhumita Sinha, M.D. · (301) 451-6237 · madhumita.sinha@nih.gov
Similar studies in Arizona
All weight loss studies in Arizona →- RecruitingHealthy volunteersPhase 3
A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
- Location
- Chandler, AZ + 55 other US sites
- Eligibility basics
- Ages 18–79
- RecruitingPhase 3
Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
Amgen
- Location
- Chandler, AZ + 51 other US sites
- Eligibility basics
- Ages 18–99
- RecruitingPhase 2
Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
AbbVie
- Location
- Scottsdale, AZ + 58 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 2
Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss
Alveus Therapeutics, Inc.
- Location
- Sun City, AZ + 19 other US sites
- Eligibility basics
- Ages 18–75